HER2/Neu/cerbB2 Antagonists

HER2/neu Receptor Antagonist

Breast Neoplasms

Gastrointestinal Neoplasms

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody and topoisomerase inhibitor conjugate. Fam-trastuzumab deruxtecan-nxki is an antibody-drug conjugate (ADC) composed of three components: 1) a humanized anti-HER2 IgG1 monoclonal antibody (mAb), covalently linked to 2) a topoisomerase inhibitor, via 3) a tetrapeptide-based cleavable linker. Deruxtecan is composed of a protease-cleavable maleimide tetrapeptide linker and the topoisomerase inhibitor, DXd, which is an exatecan derivative.</p><p>The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology, and the topoisomerase inhibitor and linker are produced by chemical synthesis. Approximately 8 molecules of deruxtecan are attached to each antibody molecule. Fam-trastuzumab deruxtecan-nxki has the following structure:</p><div class="Figure"><img alt="Chemical Structure" src="enhertu-01.jpg"/></div><p>ENHERTU (fam-trastuzumab deruxtecan-nxki) is a sterile, white to yellowish white, preservative-free lyophilized powder in single-dose vials. Each vial delivers 100 mg of fam-trastuzumab deruxtecan-nxki, L-histidine (4.45 mg), L-histidine hydrochloride monohydrate (20.2 mg), polysorbate 80 (1.5 mg), and sucrose (450 mg). Following reconstitution with 5 mL of Sterile Water for Injection, USP, the resulting concentration of fam-trastuzumab deruxtecan-nxki is 20 mg/mL with a pH of 5.5. The resulting solution is administered by intravenous infusion following dilution.</p></section>

Enhertu

trastuzumab

fam-trastuzumab deruxtecan-nxki

fam-trastuzumab deruxtecan-nxki 100 MG Injection

fam-trastuzumab deruxtecan-nxki 100 MG Injection [Enhertu]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide

Submit MSL Request 

Pharmacy List 

How To Order Enhertu 

Billing & Coding Information 

Coverage Authorization Request

Coverage Authorization Appeals

Letter of Medical Necessity 

Enhertu PA Checklist 

Enhertu4u Enrollment Form 

Enhertu4u Enrollment Form - Spanish 

Enroll in Patient Savings Program

Enroll in Patient Savings Program - HCP Office Online Portal 

Patient Assistance Program Enrollment Form - English 

Patient Assistance Program Enrollment Form - Spanish 

Independent Financial Support Programs

About Enhertu: HER2 Low MBC 

Potential Risks of Treatment: HER2 Low MBC 

Patient Resources: HER2 Low mBC

Patient Brochure: HER2 Low mBC

Side Effects Brochure: HER2 Low mBC

Care Partner Brochure: HER2 Low mBC

Discussion Guide: HER2 Low mBC

Nurse Resources

Enhertu4u Support Program 

Access and Affordibility Brochure

Patient Wallet Card

HER2 Stands With You Support Program: HER2+ mBC

About Enhertu: HER2+ mBC

Potential Risks of Treatment: HER2+ mBC

Patient Resources: HER2+ mBC

Patient Brochure: HER2+ mBC

Side Effects Brochure: HER2+ mBC

Caregiver Brochure: HER2+ mBC

Discussion Guide: HER2+ mBC

About Enhertu: HER2+ Stomach Cancer

Potential Risks of Treatment: HER2+ Stomach Cancer

Patient Resources: HER2+ Stomach Cancer 

Patient Brochure: HER2+ Stomach Cancer

Managing Side Effects Brochure: HER2+ Stomach Cancer

 About Enhertu: HER2-mutant mNSCLC

Potential Risks of Treatment: HER2-mutant mNSCLC

 Patient Resources: HER2-mutant mNSCLC

Patient Brochure: HER2-mutant mNSCLC

 Instructions For Use: HER2-mutant mNSCLC

Instructions For Use: HER2+ aGC

Instructions For Use: HER2+ mBC

Instructions For Use: HER2 Low mBC